No Data
12 Health Care Stocks Moving In Wednesday's After-Market Session
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
EXCLUSIVE: FibroBiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial for Diabetic Foot Ulcers; CYWC628 Is Multicenter Phase 1/2 Clinical Study of Fibroblast Cell Therapy In Australia
Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
Express News | Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics